

Contents

A General Introduction to Due Diligence: Look Before You Leapvii

1: Transaction Types and Gauging the Extent of Due Diligence..... 1

2: Forming Due Diligence Teams11

3: Initial Interactions with the Target (Requesting Materials,
Teleconferences and the Data Room)17

4: The Target’s Role in Due Diligence25

5: Role of the Regulatory Professional or Regulatory Legal Counsel
in Due Diligence.....29

6: Regulatory Diligence Review37

7: Supplemental Requests and Diligence Calls67

8: Chemistry, Manufacturing and Controls and Supply Chain
Diligence73

9: Nonclinical and Clinical Expert Due Diligence Roles.....83

10: Other Due Diligence Roles.....99

11: Creating and Negotiating Milestones117

12: Outputs of Due Diligence and the Final Diligence Report123

List of Abbreviations129

Index.....133

Figures

Figure 10-1. Generic Illustration of a “Treatment Tree” Format for
Understanding Patient Population Flow102

Figure 10-2. Generic Example of Patient Leakage From Using a
Treatment Decision Tree.....103

About the Authors



Joanne S. Hawana, MS, JD, is a member of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC's FDA practice team. She counsels global clients on regulatory and distribution-related considerations to bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized. Hawana also assists the Mintz corporate team by performing regulatory due diligence as part of potential mergers and acquisitions that involve regulated companies, and she often works in conjunction with the firm's intellectual property attorneys to ensure that patent and regulatory activities are strategically aligned. She holds an MS in molecular genetics and microbiology from the University of Medicine and Dentistry of New Jersey and a JD from the University of Maryland School of Law.



Benjamin M. Zegarelli, MS, JD, is a member of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC's FDA practice team. He provides counsel on compliance and regulatory issues to clients in the medical device, pharmaceutical and biotech industries. With a clear focus on FDA regulatory counseling, Zegarelli advises a breadth of health care industry and life sciences clients on the federal and state laws surrounding medical product development and marketing. He also frequently leads regulatory due diligence reviews for transactions involving pharmaceutical and medical device manufacturers and provides regulatory advice to the Mintz corporate team on such transactions. Zegarelli holds an MS in organic chemistry from the California Institute of Technology and a JD from the Benjamin N. Cardozo School of Law.



Elizabeth K. Conti, JD, is a member of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC's FDA practice team. She focuses her practice on regulatory compliance and enforcement defense matters for companies in pharmaceuticals, medical device, dietary supplement, cosmetics and food industries as well as pharmacies and distributors. Conti advises clients on FDA regulations related to labeling, advertising, importing and exporting, and manufacturing practices. Her practice also encompasses administrative matters and civil litigation related to DEA requirements. Conti holds a JD from the Catholic University of America.



Scott P. Dunberg, JD, is a member of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC's corporate and securities practice team. He represents public and private companies in a broad range of transactions and corporate matters and focuses primarily on mergers and acquisitions, venture capital financings, capital markets transactions, securities law compliance and general corporate representation. Dunberg regularly represents technology-based companies, principally in the areas of biotechnology, med-tech, telecommunications, and software. He holds a JD from Suffolk University Law School.